Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

apolizumab

Known as: Monoclonal Antibody Hu1D10, MOAB Hu1D10, Monoclonal antibody 1D10 
A humanized monoclonal antibody directed against 1D10, a polymorphic determinant on the HLA-DR beta chain that is expressed on normal and neoplastic… Expand
National Institutes of Health

Related topics

Related topics

10 relations

Broader (2)

Antibodies, Monoclonal, HumanizedMonoclonal Antibodies
Antibody-Dependent Cellular CytotoxicityB-LymphocytesComplement-Dependent CytotoxicityHLA-DR Antigens
Expand

Narrower (2)

Hu1D 10Remitogen

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia
Apolizumab (Hu1D10), a humanized monoclonal anti- Human leukocyte antigen -DR β-chain antibody, mediates apoptosis of chronic… Expand
2008
2008
Caracterização funcional do anticorpo monoclonal humano BH1
Embora, existam novas terapias e avancos no tratamento do cancro, por vezes, os beneficios esperados nao sao alcancados. O drama… Expand
2006
2006
A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: A pilot study
Apolizumab is a humanized monoclonal antibody against a polymorphic epitope on HLA DRβ that demonstrated evidence for therapeutic… Expand
2005
2005
Phase 1 study of combination rituximab with apolizumab in relapsed/refractory B-cell lymphoma and chronic lymphocytic leukemia
6607 Background: Apolizumab (Apo), a humanized IgG1 mAb, targets ID10, and rituximab (R), a chimeric IgG1 mAb, targets CD20, both… Expand
2005
2005
In Vitro Activity of the Humanized Anti-HLA-DR Antibodies KRN848 and Apolizumab in Non-Hodgkins Lymphoma Cell Lines.
Apolizumab (Hu1D10) and KRN848 are humanized IgG1 anti-HLA-DR monoclonal antibodies (mAb). Apolizumab binds a polymorphic… Expand
2004
2004
Hu 1 D 10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells
The 1D10 antigen is the target for Hu1D10 (apolizumab), a humanized HLA-DR -chain–specific antibody that is currently in clinical… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2003
Review
2003
Monoclonal antibody therapy of chronic lymphocytic leukemia.
Chemotherapeutic approaches during the last decade have failed to result in major advances in the outcome of patients with… Expand
2003
2003
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… Expand
2002
2002
Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).
Clinical activity of anti-CD20 monoclonal antibodies both in the unlabeled (rituximab [Rituxan; Genentech, Inc, South San… Expand
Review
2002
Review
2002
Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).
Clinical activity of anti-CD20 monoclonal antibodies both in the unlabeled (rituximab [Rituxan; Genentech, Inc, South San… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE